Is Novo Nordisk a Victim of Success or Hubris with Semaglutide?
July 2, 2025 — A new report from Reuters tells us that Novo Nordisk is having a hard time coming to terms with its failure to solidify a leadership position in the obesity market it created from nothing with semaglutide. Former executives and financial analysts alike say the company was too conservative and unprepared for a blockbuster launch: “way, way, […]
